Trial Profile
An Open-label, Exploratory, Multicenter, Dose-escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures (Whether or Not Secondarily Generalized) and Treated With 1, 2 or 3 Approved Antiepileptic Drugs
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Seletracetam (Primary)
- Indications Epilepsy; Partial epilepsies
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 17 Aug 2006 Status change
- 29 Dec 2005 New trial record.